These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 34362343)

  • 21. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
    D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
    Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
    Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
    Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for colorectal neoplasias with fecal occult blood tests: false-positive impact of non-dietary restriction.
    Roslani AC; Abdullah T; Arumugam K
    Asian Pac J Cancer Prev; 2012; 13(1):237-41. PubMed ID: 22502676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.
    Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA
    Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
    Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
    PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interval Colorectal Cancers following Guaiac Fecal Occult Blood Testing in the Ontario ColonCancerCheck Program.
    Paszat L; Sutradhar R; Tinmouth J; Baxter N; Rabeneck L
    Can J Gastroenterol Hepatol; 2016; 2016():4768728. PubMed ID: 27446842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guaiac faecal occult blood screening in individuals younger than 50 years of age.
    Zalts R; Moadi Z; Avizohar O; Leiba R; Half E; Karban A
    Eur J Cancer Prev; 2017 May; 26(3):189-194. PubMed ID: 27167151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme.
    Kearns B; Whyte S; Chilcott J; Patnick J
    Br J Cancer; 2014 Oct; 111(9):1734-41. PubMed ID: 25180767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Transitioning From Guaiac-Fecal Occult Blood Testing to Fecal Immunochemical Testing in a Canadian Colon Cancer Screening Program.
    Sultanian R; Du L; Moysey B; Morse A; Veldhuyzen van Zanten S; Montano-Loza AJ
    J Can Assoc Gastroenterol; 2020 Aug; 3(4):177-184. PubMed ID: 32671327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
    Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
    Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial.
    Coronado GD; Petrik AF; Vollmer WM; Taplin SH; Keast EM; Fields S; Green BB
    JAMA Intern Med; 2018 Sep; 178(9):1174-1181. PubMed ID: 30083752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
    Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
    J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.